疫情

待確認美国开发的remdesivir 是什么？

基于患者的胸片结果，以及持续高烧，需要吸氧，且多个部位的样本出现新型冠状病毒的阳性结果，医生们决定为其提供一种尚未获批的药物——由吉利德（Gilead）公司研发的抗病毒药remdesivir。这是一种核苷酸类似物前药，能够抑制依赖RNA的RNA合成酶（RdRp）。在住院的第七天晚上，这名患者接受了remdesivir的静脉输注。第八天，这名患者的临床症状出现了立竿见影的改善。

论文原文：First Case of 2019 Novel Coronavirus in the United States
https://www.nejm.org/doi/full/10.1056/NEJMoa2001191

看到五毛也在发YouTube了，不知道这个东西是什么

时间
票数

8 个回复

洋葱韭菜一家亲

请看这个博客：http://www.virology.ws/

Can infection be prevented or cured?

A number of experimental vaccines for 2019-nCoV have been announced, but it is unlikely that they will be available to halt the current outbreak. Nevertheless, they should be pursued should the virus become endemic in humans (unlike SARS-CoV, which has not been seen since).

Antiviral drugs would be useful for treatment of very sick patients. Remdesvir, a nucleotide analog with potent antiviral activity against a wide range of RNA viruses, including ebolaviruses, MERS-CoV, and SARS-CoV, should be tested for efficacy against 2019-CoV. It has been shown to be superior to a combination of lopinavir, ritonavir, and interferon beta, which is being evaluated for treatment of MERS-CoV and 2019-CoV infections in humans. With multiple 2019-nCoV virus isolates available, it will be possible to test other existing antivirals or identify new ones.

Remdesvir是一个需要通过身体代谢才会转化成有药性作用的抗病毒药物。目前还在试验阶段，可是因为对Ebola和不同分支的coronavirus貌似有更优于市面anti-viral的性能，正在被高速推。Remdesvir对2019-nCoV有没有效，资料不足，正在研究。

上面的博客个人推荐。~~推特上的Eric Ding辟谣和消息整理连载也推荐。~~

Eric Ding资格和信息质量有待商讨。